Already in July 2021, Eisbach Bio received a Funding of over 8 million euros from the Federal Ministry of Education and Research. Now, the Bavarian State Ministry for Economic Affairs, Regional Development and Energy is also supporting the preclinical and clinical development of an active ingredient against the coronavirus SARS-CoV-2. The funding is intended to maintain the competitiveness of the biotech scene in Bavaria. Eisbach Bio is located in the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich. The Eisbach CEO Adrian Schomburg says:
"Our team is grateful for the government support in developing our drug candidates. The biotech scene in Bavaria and beyond will benefit from this project. Our research progress demonstrates how Bavarian companies are committed to the fight against COVID-19 and are playing a leading role in developing innovations and therapeutic solutions."
Eisbach Bio: “Urgently needed new antiviral drug for the global community”
Andreas Ladurner, CSO at Eisbach Bio, adds:
"We are committed to developing a sustainable drug with a good safety profile. The funded BayTherapy2020 program will allow us to allocate more resources to the research and development of EIS4363, significantly increasing our chances of developing a much-needed new antiviral drug for the global community."
Eisbach's goal is to bring a safe, sustainable, and targeted antiviral drug with specific activity against the SARS-CoV-2 virus into the clinic. This will slow the progression of the disease and end the pandemic worldwide. The company plans to begin Phase I clinical trials for its drug in the second quarter of 2022.
"We are very proud that a startup from the IZB is making a significant contribution to the global fight against the coronavirus pandemic. We wish the Eisbach Bio team every success in implementing their innovative technology,"
says Peter Hanns Zobel, Managing Director of the IZB.
